Literature DB >> 18846002

Antineoplastic properties of bacteriocins: revisiting potential active agents.

Gilbert Cornut1, Claude Fortin, Denis Soulières.   

Abstract

Bacteriocins are antimicrobial peptides produced by a wide range of bacteria. Their antineoplastic properties have been inadequately revealed in the late 70s by using crude bacteriocin preparation toxic to mammalian cells. Nowadays, purified bacteriocins are available and have shown inhibitory properties toward diverse neoplastic line cells. Pyocin, colicin, pediocin, and microcin are among bacteriocins reported to present such activity. Moreover, modified bacteriocins proved to be effective in a glioblastoma xenograft mouse model. Screening for the presence of bacteriocin in colon cancer subjects has been studied with mixed results. Bacteriocin use as a therapeutic agent or in a prevention setting is discussed specifically evaluating bacteriocins biochemical properties and recent advances in peptide therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18846002     DOI: 10.1097/COC.0b013e31815e456d

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  16 in total

1.  Potential Applications of the Cyclic Peptide Enterocin AS-48 in the Preservation of Vegetable Foods and Beverages.

Authors:  Hikmate Abriouel; Rosario Lucas; Nabil Ben Omar; Eva Valdivia; Antonio Gálvez
Journal:  Probiotics Antimicrob Proteins       Date:  2010-06       Impact factor: 4.609

2.  Accumulation of single-stranded DNA in Escherichia coli carrying the colicin plasmid pColE3-CA38.

Authors:  Magali Morales; Hedieh Attai; Kimberly Troy; David Bermudes
Journal:  Plasmid       Date:  2014-11-05       Impact factor: 3.466

3.  Antimicrobial peptide m2163 or m2386 identified from Lactobacillus casei ATCC 334 can trigger apoptosis in the human colorectal cancer cell line SW480.

Authors:  Tsung-Lin Tsai; An-Chieh Li; Yi-Chieh Chen; Yi-Shun Liao; Thy-Hou Lin
Journal:  Tumour Biol       Date:  2015-01-05

4.  Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents.

Authors:  María Ángeles Abengózar; Rubén Cebrián; José María Saugar; Teresa Gárate; Eva Valdivia; Manuel Martínez-Bueno; Mercedes Maqueda; Luis Rivas
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 5.  Biomedical applications of nisin.

Authors:  J M Shin; J W Gwak; P Kamarajan; J C Fenno; A H Rickard; Y L Kapila
Journal:  J Appl Microbiol       Date:  2016-02-12       Impact factor: 3.772

6.  Identification & Characterization of lactobacillus salavarius bacteriocins and its relevance in cancer therapeutics.

Authors:  Faraz Shaikh; Pa Abhinand; Pk Ragunath
Journal:  Bioinformation       Date:  2012-07-06

7.  Development of Class IIa Bacteriocins as Therapeutic Agents.

Authors:  Christopher T Lohans; John C Vederas
Journal:  Int J Microbiol       Date:  2011-11-30

8.  Nisin ZP, a Bacteriocin and Food Preservative, Inhibits Head and Neck Cancer Tumorigenesis and Prolongs Survival.

Authors:  Pachiyappan Kamarajan; Takayuki Hayami; Bibiana Matte; Yang Liu; Theodora Danciu; Ayyalusamy Ramamoorthy; Francis Worden; Sunil Kapila; Yvonne Kapila
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

9.  Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia.

Authors:  Darina Kohoutova; David Smajs; Paula Moravkova; Jiri Cyrany; Monika Moravkova; Miroslava Forstlova; Michal Cihak; Stanislav Rejchrt; Jan Bures
Journal:  BMC Infect Dis       Date:  2014-12-24       Impact factor: 3.090

Review 10.  Bacteriocins as Potential Anticancer Agents.

Authors:  Sumanpreet Kaur; Sukhraj Kaur
Journal:  Front Pharmacol       Date:  2015-11-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.